Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis in the zone

Executive Summary

Novartis' hypertension programs have improved compliance by 50 percent, the firm reports during its Q4 earnings call Jan. 18. Novartis has enrolled 500,000 patients worldwide in its "BP Zone" compliance initiative, a part of its "category captainship" strategy to enhance its leadership position in the hypertension market. Novartis is offering patients assistance with managing blood pressure by offering blood pressure monitors, information services and an educational Web site (1"The Pink Sheet" Oct. 30, 2006, p. 13). "We believe based on our analysis that those patients which were enrolled and stayed on the program, the compliance rate was increased by 50 percent," CEO Thomas Ebeling says. "That's one of the reasons why our market share in the U.S. has recovered"...

You may also be interested in...



Novartis’ “Captainship” Program Produces More Hypertension Market Share

Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market

Formycon And Bioeq Offer Ranibizumab Update

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.

Oxular Sets Out Eye Disease Plans Armed With $37m

The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel